1. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010; 6:30–8.
Article
2. Terkeltaub R, Zelman D, Scavulli J, Perez-Ruiz F, Lioté F. Gout Study Group: update on hyperuricemia and gout. Joint Bone Spine. 2009; 76:444–6.
Article
3. Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr Opin Rheumatol. 2009; 21:143–9.
Article
4. Osada Y, Tsuchimoto M, Fukushima H, Takahashi K, Kondo S, Hasegawa M, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol. 1993; 241:183–8.
Article
5. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet. 2006; 45:821–41.
Article
6. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel nonpurine inhibitor of xanthine oxidase/xanthine dehy-drogenase. Life Sci. 2005; 76:1835–47.
Article
7. Komoriya K, Osada Y, Hasegawa M, Horiuchi H, Kondo S, Couch RC, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol. 1993; 250:455–60.
Article
8. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12:R63.
Article
9. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009; 36:1273–82.
Article
10. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59:1540–8.
Article
11. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353:2450–61.
Article
12. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005; 52:916–23.
Article
13. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977; 20:895–900.
Article
14. Gray CL, Walters-Smith NE. Febuxostat for treatment of chronic gout. Am J Health Syst Pharm. 2011; 68:389–98.
Article
15. Lee MH, Graham GG, Williams KM, Day RO. A bene-fit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best in-terest of patients? Drug Saf. 2008; 31:643–65.
Article
16. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunaward-hana L. Renal function in gout: longterm treatment effects of febuxostat. J Clin Rheumatol. 2011; 17:7–13.
17. Bardin T. Current management of gout in patients un-responsive or allergic to allopurinol. Joint Bone Spine. 2004; 71:481–5.
Article